Part 1B - AMG 176 and Azacitidine Combination Therapy (Dose Exploration) for Chronic Myelomonocytic Leukemia
Study Summary
This trialtests a new drug to treat HR-MDS/CMML, to see if it is safe, tolerable and effective.
- Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndrome (MDS)
Treatment Effectiveness
Effectiveness Progress
Study Objectives
3 Primary · 19 Secondary · Reporting Duration: Up to 1.5 years
Trial Safety
Safety Progress
Trial Design
3 Treatment Groups
Part 1B - AMG 176 and Azacitidine Combination Therapy (Dose Exploration)
1 of 3
Part 1A - AMG 176 Monotherapy (Dose Exploration)
1 of 3
Part 2 - AMG 176 and Azacitidine Combination Therapy (Dose Expansion)
1 of 3
Experimental Treatment
120 Total Participants · 3 Treatment Groups
Primary Treatment: Part 1B - AMG 176 and Azacitidine Combination Therapy (Dose Exploration) · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 85 · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Does the trial accept participants who have surpassed four decades of life?
"For this clinical trial, the accepted age range for participants is 18 to 85 years old." - Anonymous Online Contributor
Who has been granted access to participate in this clinical research?
"This clinical trail is searching for 120 individuals suffering from leukimia, myelomonocytic and chronic illnesses to participate. Patients must between 18 and 85 years of age in order to be accepted into the trial." - Anonymous Online Contributor
What is the upper-bound of individuals participating in this clinical exploration?
"Affirmative. Clinicaltrials.gov has the information indicating that this trial is presently looking for qualified candidates, and was incepted on November 15th 2022 with a recent update occurring just last week on November 22nd 2022. The study requires 120 volunteers from one medical facility." - Anonymous Online Contributor
Has the FDA given their sanction to study the efficacy of a conjoint treatment with AMG 176 and Azacitidine?
"There is limited data to support the safety and efficacy of Part 1B - AMG 176 in conjunction with Azacitidine Combination Therapy (Dose Exploration) so a score of one was given." - Anonymous Online Contributor
Is this trial actively looking for volunteers?
"Affirmative. The clinicaltrials.gov database indicates that this medical trial, which was first published on November 15th 2022, is still actively enrolling patients. Approximately 120 people must be enrolled at 1 study site." - Anonymous Online Contributor